Boise Cascade Company logo

Boise Cascade Company (BCC)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
68. 68
-0.54
-0.78%
$
2.4B Market Cap
- P/E Ratio
0.84% Div Yield
280,762 Volume
- Eps
$ 69.22
Previous Close
Add Transaction
Day Range
68.37 69.36
Year Range
65 95
Want to track BCC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
New Strong Sell Stocks for May 28th

New Strong Sell Stocks for May 28th

BCC, DOOO and CMT have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2025.

Zacks | 1 year ago
Boise Cascade Company (BCC) Q1 2025 Earnings Call Transcript

Boise Cascade Company (BCC) Q1 2025 Earnings Call Transcript

Boise Cascade Company (NYSE:BCC ) Q1 2025 Earnings Conference Call May 6, 2025 9:30 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Joanna Barney - EVP, Building Materials Distribution Conference Call Participants Susan Maklari - Goldman Sachs Kurt Yinger - D.A. Davidson George Staphos - Bank of America Securities Zack Pacheco - Loop Capital Markets Ketan Mamtora - BMO Capital Markets Reuben Garner - Benchmark Operator Good morning.

Seekingalpha | 1 year ago
Boise Cascade Q1 Earnings Miss Estimates, Sales Beat, Stock Dips

Boise Cascade Q1 Earnings Miss Estimates, Sales Beat, Stock Dips

BCC's first-quarter 2025 results reflect lower volumes and unfavorable sales price trends across product categories.

Zacks | 1 year ago
Boise Cascade (BCC) Lags Q1 Earnings Estimates

Boise Cascade (BCC) Lags Q1 Earnings Estimates

Boise Cascade (BCC) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $2.61 per share a year ago.

Zacks | 1 year ago
Boise Cascade Reports Lower Sales, Profit as Home Construction Slows

Boise Cascade Reports Lower Sales, Profit as Home Construction Slows

The maker of wood products said the 2025 market demands are difficult to predict, with most forecasts for housing starts ranging from flat to mid-single-digit declines, year-over-year.

Wsj | 1 year ago
Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for

Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Boise Cascade: Priced For A Recession, But Built To Survive It

Boise Cascade: Priced For A Recession, But Built To Survive It

Boise Cascade, a leading wood products' manufacturer, is rated a Buy due to its strong balance sheet and long-term housing market tailwinds, despite short-term cyclical challenges. The company benefits from vertical integration, sourcing raw timber cost-effectively, and distributing finished lumber products to major retailers and builders. BCC's financial health is robust, with a low debt/equity ratio and significant cash reserves, positioning it well to weather economic downturns.

Seekingalpha | 1 year ago
Buying A Dollar For 60 Cents: 2 Dividend Stocks With Potential Upside

Buying A Dollar For 60 Cents: 2 Dividend Stocks With Potential Upside

The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies with strong fundamentals. I focus on businesses with resilient models, growth potential, and attractive valuations. Despite headline risks, I believe in their ability to navigate uncertainty and deliver long-term returns. While risks like prolonged trade tensions or economic slowdowns exist, I remain confident in my picks, as they are well-positioned to thrive regardless of short-term market turbulence.

Seekingalpha | 1 year ago
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results

Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results

Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.

Proactiveinvestors | 1 year ago
Boise Cascade Q4 Earnings Miss, Sales Top, Adjusted EBITDA Down Y/Y

Boise Cascade Q4 Earnings Miss, Sales Top, Adjusted EBITDA Down Y/Y

BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.

Zacks | 1 year ago
Boise Cascade Company, Inc. (BCC) Q4 2024 Earnings Call Transcript

Boise Cascade Company, Inc. (BCC) Q4 2024 Earnings Call Transcript

Boise Cascade Company, Inc. (NYSE:BCC ) Q4 2024 Earnings Conference Call February 21, 2025 11:00 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Conference Call Participants Kurt Yinger - D.A. Davidson Susan Maklari - Goldman Sachs Mike Roxland - Truist Securities George Staphos - Bank of America Merrill Lynch Ketan Mamtora - BMO Capital Markets Operator Good morning.

Seekingalpha | 1 year ago
Boise Cascade (BCC) Q4 Earnings Lag Estimates

Boise Cascade (BCC) Q4 Earnings Lag Estimates

Boise Cascade (BCC) came out with quarterly earnings of $1.78 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $2.44 per share a year ago.

Zacks | 1 year ago
Loading...
Load More